scholarly journals Prevalence of Comorbidity and Impact On Survival in Women with Lung, Breast and Cervical Cancer

2021 ◽  
Vol 5 (1) ◽  
Keyword(s):  
Breast Cancer ◽  
Cervical Cancer ◽  
Cox Regression ◽  
The Elderly ◽  
Breast And Cervical Cancer ◽  
Incidence And Mortality ◽  
Impact On Survival ◽  
Icd 10 ◽  
Comorbidity Index ◽  
The Relationship

Background: The relationship between cancer incidence and mortality, and the resulting comorbidities of the elderly reflects current demographics trends Objective: The study aimed to investigate the prevalence of comorbidities and their impact on survival of women diagnosed with: NSCLC, breast and cervical cancer, at the National Institute of Oncology and Radiobiology in Havana, Cuba. Methods: Data were collected retrospectively from patients' clinical charts. The study involved 138 NSCLC, 1 598 breast cancer and 631 cervical cancer registered during 2007-2011. Comorbidity was classified according to the ICD-10 diagnosis code and was measured using Charlson Comorbidity Index. Associations between comorbidities and mortality by all causes were analyzed in Cox regression models. Results: The highest prevalence of comorbidities was in NSCLC (68.8%). The 3-year OS for NSCLC were 44.5% (95%CI: 29.3–59.7) and 23.3% (95%CI: 13.2–33.4) in patients without and with comorbidity, respectively (p=.01). The 5-year OS for breast cancer in the no comorbidity group was 91.4% (95%CI: 89.6–91.6) compared with 37.2% (95%CI: 32.7-59.9) in the comorbodity group (p=.00). The 5-year OS for cervical cancer in patients without diseases was (55.8% [95%CI: 50.7 – 59.9]), in women with comorbidity (27.7% [95%CI: 15.9–29.5]) (p =.00). Comorbidity was an independent predictor for overall survival: NSCL (HR Adjusted: 2.28 [95%CI: 1.43 - 3.65], p=.000), breast cancer (HR Adjusted: 3.16 [95%CI: 2.69–3.71], p=.000), cervical cancer (HR Adjusted: 1.38 [95%CI: 1.10–1.86], p=.032) Conclusions: Comorbidity is an important prognostic factor for women diagnosed with lung, breast and cervical cancer

Breast and cervical cancer incidence and mortality trends in Russia 1980–2013

2018 ◽  
Vol 55 ◽  
pp. 73-80 ◽  
Author(s):  
Anton Barchuk ◽  
Alexander Bespalov ◽  
Heini Huhtala ◽  
Tuvshinjargal Chimed ◽  
Irina Laricheva ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Cancer Incidence ◽  
Cervical Cancer Incidence ◽  
Mortality Trends ◽  
Breast And Cervical Cancer ◽  
Incidence And Mortality

Rate of depressive episode in Peruvian oncologic outpatients.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. e12043-e12043
Author(s):  
Luis Furuya ◽  
Erick Infanzon ◽  
Diego Venegas
Keyword(s):  
Breast Cancer ◽  
Depressive Episode ◽  
Financial Status ◽  
The Poor ◽  
Epidemiological Features ◽  
Two Factors ◽  
Icd 10 ◽  
The Mean ◽  
The Relationship ◽  
Transversal Study

e12043 Background: Depression in Lima, Peru has a prevalence rate of 6.7% and lifetime prevalence of 19%. The relationship between depression and cancer has been widely studied, affects approximately 15% to 25% of cancer patients. However, there is little research in latin population. We report the results of evaluate the frequency of depressive disorder in Peruvian oncologic outpatients and describe clinical and epidemiological features Methods: A descriptive transversal study was performed to 70 patients that attended to oncology clinic at the Hospital Nacional Cayetano Heredia. Data was collected through a survey that included a clinical demographic record and the spanish version – ICD 10 of the Mini International Neuropsychiatric Interview for the diagnosis of depressive episode. Results: The 52% of the participants were females. The mean age was 57 years (18- 83 y) Breast cancer (21%) and lymphoma non Hodgkin (21%) were the most common types of cancer. The mean period from diagnosis was 5 month. The frequency of depressive episode was 21.4%. The 33.3% of women with breast cancer had depression, while patients with NHL had only 13.3% of frequency. We founded two factors with statistically significant association: poor financial status (p =0.041) and advance clinical stages (III and IV) (p = 0.026; OR: 6.8) Conclusions: The frequency of depressive episode was similar to other reports in the literature, the poor financial status and advanced stage are most associated with depression in our population

Prognostic Survival Factors in Elderly Renal Failure Patients Treated with Peritoneal Dialysis: A Nine-Year Retrospective Study

2010 ◽  
Vol 30 (2) ◽  
pp. 218-226 ◽  
Author(s):  
Sandrine Genestier ◽  
Nicolas Meyer ◽  
François Chantrel ◽  
Farideh Alenabi ◽  
Pierre Brignon ◽  
...  
Keyword(s):  
Peritoneal Dialysis ◽  
Elderly Patients ◽  
Family Environment ◽  
Cox Model ◽  
The Elderly ◽  
Predictive Variables ◽  
The Social ◽  
Impact On Survival ◽  
Considerable Impact ◽  
Comorbidity Index

BackgroundFew studies specifically investigating elderly patients on peritoneal dialysis (PD) have been conducted and great uncertainty remains on the factors involved in the vital prognosis. The objective of this study was to describe our population of patients aged 75 years or older at the time PD was initiated and to study their survival in terms of the relevant nephro-geriatric criteria inventoried at the beginning of treatment.MethodsWe retrospectively analyzed the data of all the elderly patients that began first-line PD in our center between 1 January 1997 and 31 July 2006 ( n = 112).ResultsMean duration of survival on PD was 19.6 ± 13.9 months; by the end of the study 87 patients had died and 7 had been transferred to hemodialysis. The Cox model multivariate analysis of survival allowed us to select 5 independent predictive variables that had a considerable impact on survival: absence of nephrologic care before dialysis, associated comorbidities (Charlson Comorbidity Index), loss of physical and/or mental autonomy (AGGIR group), and polymedication. Above and beyond the weight of these clinical variables, institutionalization or, more generally, social isolation was a determining factor for the duration of survival in PD.ConclusionAny patient considered for peritoneal dialysis should be evaluated by a multidisciplinary team in collaboration with geriatric specialists for both the overall medical situation and the social and family environment.

Are allopurinol dose and duration of use nephroprotective in the elderly? A Medicare claims study of allopurinol use and incident renal failure

2016 ◽  
Vol 76 (1) ◽  
pp. 133-139 ◽  
Author(s):  
Jasvinder A Singh ◽  
Shaohua Yu
Keyword(s):  
Renal Failure ◽  
Lower Risk ◽  
Cox Regression ◽  
The Elderly ◽  
Baseline Period ◽  
Sensitivity Analyses ◽  
Medicare Claims ◽  
Comorbidity Index ◽  
Stage Renal Disease ◽  
End Stage

ObjectiveTo assess the effect of allopurinol dose/duration on the risk of renal failure in the elderly with allopurinol use.MethodsWe used the 5% random Medicare claims data from 2006 to 2012. Multivariable-adjusted Cox regression analyses assessed the association of allopurinol dose/duration with subsequent risk of developing incident renal failure or end-stage renal disease (ESRD) (no prior diagnosis in last 183 days) in allopurinol users, controlling for age, sex, race and Charlson–Romano comorbidity index. HRs with 95% CIs were calculated. Sensitivity analyses considered a longer baseline period (365 days), controlled for gout or used more specific codes.ResultsAmong the 30 022 allopurinol treatment episodes, 8314 incident renal failure episodes occurred. Compared with 1–199 mg/day, allopurinol dose of 200–299 mg/day (HR 0.81; 95% CI 0.75 to 0.87) and ≥300 mg/day, 0.71 (0.67 to 0.76), had significantly lower hazard of renal failure in multivariable-adjustment model, confirmed in multiple sensitivity analyses. Longer allopurinol use duration was significantly associated with lower hazards in sensitivity analyses (365-day look-back; reference, <0.5 year): 0.5–1 year, 1.00 (0.88, 1.15); >1–2 years, 0.85 (0.73 to 0.99); and >2 years, 0.81 (0.67 to 0.98). Allopurinol ≥300 mg/day was also associated with significantly lower risk of acute renal failure and ESRD with HR of 0.89 (0.83 to 0.94) and 0.57 (0.46 to 0.71), respectively.ConclusionsHigher allopurinol dose is independently protective against incident renal failure in the elderly allopurinol users. A longer duration of allopurinol use may be associated with lower risk of incident renal failure. Potential mechanisms of these effects need to be examined.

scholarly journals Identification of a Novel Glycolysis-Related Signature to Predict the Prognosis of Patients with Breast Cancer

2021 ◽  
Author(s):  
Menglin He ◽  
Cheng Hu ◽  
Jian Deng ◽  
Hui Ji ◽  
Weiqian Tian
Keyword(s):  
Breast Cancer ◽  
Risk Score ◽  
Cox Regression ◽  
Risk Group ◽  
Gene Signature ◽  
High Risk Group ◽  
Low Risk ◽  
Cox Regression Analysis ◽  
Expression Levels ◽  
Incidence And Mortality

Abstract Background: Breast cancer (BC) is a kind of cancer with high incidence and mortality in female. Conventional clinical characteristics are far from accurate to predict individual outcomes. Therefore, we aimed to develop a novel signature to predict the survival of patients with BC. Methods: We analyzed the data of a training cohort from the TCGA database and a validation cohort from GEO database. After the applications of GSEA and Cox regression analyses, a glycolysis-related signature for predicting the survival of patients with BC was developed. The signature contains AK3, CACNA1H, IL13RA1, NUP43, PGK1, and SDC1. Then, we constructed a risk score formula to classify the patients into high and low-risk groups based on the expression levels of six-gene in patients. The receiver operating characteristic (ROC) curve and the Kaplan-Meier curve were used to assess the predicted capacity of the model. Next, a nomogram was developed to predict the outcomes of patients with risk score and clinical features in 1, 3, and 5 years. We further used Human Protein Atlas (HPA) database to validate the expressions of the six biomarkers in tumor and sample tissues.Results: We constructed a six-gene signature to predict the outcomes of patients with BC. The patients in high-risk group showed poor prognosis than that in low-risk group. The AUC values were 0.719 and 0.702, showing that the prediction performance of the signature is acceptable. Additionally, Cox regression analysis revealed that these biomarkers could independently predict the prognosis of BC patients without being affected by clinical factors. The expression levels of all six biomarkers in BC tissues were higher than that in normal tissues except AK3. Conclusion: We developed a six-gene signature to predict the prognosis of patients with BC. Our signature has been proved to have the ability to make an accurate and obvious prediction and might be used to expand the prediction methods in clinical.

Sign in / Sign up

Export Citation Format

Share Document